4.7 Article

Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: association with soluble MICA shedding

期刊

CANCER IMMUNOLOGY IMMUNOTHERAPY
卷 61, 期 8, 页码 1201-1210

出版社

SPRINGER
DOI: 10.1007/s00262-011-1195-z

关键词

Chronic lymphocytic leukemia; NKG2D; MICA; ERp5; GRP78; NK cells

资金

  1. Spanish grants of Fondo de Investigaciones Sanitarias (Institute Carlos III) [PS09/00420, FIS PI08/0566]
  2. FICYT of Asturias [BP06-99]

向作者/读者索取更多资源

MICA is a ligand of the activating receptor NKG2D, expressed by NK and T cells. MICA expression is induced in cancer cells favoring their elimination by the immune system; however, many advanced tumors shed soluble MICA (sMICA), which impairs NKG2D-mediated cytotoxicity. ERp5 and GRP78 are endoplasmic reticulum-resident proteins that are translocated to the surface of epithelial tumor cells where they interact with MICA and are involved in sMICA shedding. In this study, we analyze the role of ERp5 and GRP78 in sMICA shedding in chronic lymphocytic leukemia (CLL). Immunofluorescence and flow cytometry analyses showed that ERp5 and GRP78 were significantly expressed on the surface of B cells and leukemia cells, but they were not expressed on T cells. The expression of ERp5 and GRP78 was significantly higher in leukemia cells than in B cells from controls. ERp5 and GRP78 co-localized with MICA on the surface of leukemia cells and the levels of expression of ERp5 and GRP78 correlated with the level of expression of membrane-bound MICA in CLL patients. Associated with higher expression of membrane-bound ERp5 and GRP78, serum sMICA levels were approximately threefold higher in patients than in controls. Elevated sMICA levels in CLL patients were associated with the down-modulation of NKG2D surface expression on CD8 T cells. Finally, pharmacological inhibition of B cell lines and stimulated leukemia cells showed that ERp5 activity is involved in sMICA shedding in CLL. In conclusion, these results uncover a molecular mechanism which regulates MICA protein shedding and immune evasion in CLL.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma

Camila Guerrero, Noemi Puig, Maria-Teresa Cedena, Ibai Goicoechea, Cristina Perez, Juan-Jose Garces, Cirino Botta, Maria-Jose Calasanz, Norma C. Gutierrez, Maria-Luisa Martin-Ramos, Albert Oriol, Rafael Rios, Miguel-Teodoro Hernandez, Rafael Martinez-Martinez, Joan Bargay, Felipe de Arriba, Luis Palomera, Ana Pilar Gonzalez-Rodriguez, Adrian Mosquera-Orgueira, Marta-Sonia Gonzalez-Perez, Joaquin Martinez-Lopez, Juan-Jose Lahuerta, Laura Rosinol, Joan Blade, Maria-Victoria Mateos, Jesus F. San-Miguel, Bruno Paiva

Summary: This study established a comprehensive weighted model using machine learning algorithms to accurately predict undetectable measurable residual disease (MRD) outcomes in multiple myeloma patients, providing a new concept for personalized treatment.

CLINICAL CANCER RESEARCH (2022)

Article Medicine, Research & Experimental

Involvement of CD4+ and CD8+ T-lymphocytes in the modulation of nociceptive processing evoked by CCL4 in mice

Sara Gonzalez-Rodriguez, Seila Lorenzo-Herrero, Christian Sordo-Bahamonde, Agustin Hidalgo, Segundo Gonzalez, Luis Menendez, Ana Baamonde

Summary: The study found that CCL4-induced hyperalgesia is related to the desensitization of CCR5 in CD4(+) T-cells and to the release of IL-16 from CD8(+) lymphocytes.

LIFE SCIENCES (2022)

Article Oncology

Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma

Luis-Esteban Tamariz-Amador, Paula Rodriguez-Otero, Ana Jimenez-Ubieto, Laura Rosinol, Albert Oriol, Rafael Rios, Anna Sureda, Maria Jesus Blanchard, Miguel Teodoro Hernandez, Valentin Cabanas Perianes, Isidro Jarque, Juan Bargay, Mercedes Gironella, Felipe De Arriba, Luis Palomera, Yolanda Gonzalez-Montes, Josep M. Marti, Isabel Krsnik, Jose Maria Arguinano, Maria Esther Gonzalez, Luis Felipe Casado, Ana Pilar Gonzalez-Rodriguez, Lucia Lopez-Anglada, Noemi Puig, Maria Teresa Cedena, Bruno Paiva, Maria-Victoria Mateos, Jesus San-Miguel, Juan-Jose Lahuerta, Joan Blade, Inaki F. Troconiz

Summary: Response kinetics in multiple myeloma have been studied using a mathematical model to assess the prognostic value of serum monoclonal component (MC) response kinetics. The study identified two patient subgroups with significantly different progression-free survival based on the resistance parameter calculated by the model.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

Article Oncology

Immunoglobulin-like transcript 2 blockade restores antitumor immune responses in glioblastoma

Seila Lorenzo-Herrero, Christian Sordo-Bahamonde, Alejandra Martinez-Perez, Ma Daniela Corte-Torres, Ivan Fernandez-Vega, Ma Pilar Solis-Hernandez, Segundo Gonzalez

Summary: Glioblastoma is a common primary brain tumor, and immune checkpoint blockade strategies may offer a novel therapy for improving patient outcomes. ILT2 blockade has been found to promote an immune response against glioblastoma, and co-treatment with temozolomide enhances its efficacy.

CANCER SCIENCE (2023)

Article Oncology

Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM)

Ana Villalba, Ana Pilar Gonzalez-Rodriguez, Javier Arzuaga-Mendez, Noemi Puig, Mario Arnao, Jose Maria Arguinano, Maria Jimenez, Marta Canet, Ana Teruel, Maria Sola, Francisco J. Diaz, Cristina Encinas, Antonio Garcia, Laura Rosinol, Alexia Suarez, Marta Sonia Gonzalez, Isabel Izquierdo, Miguel Teodoro Hernandez, Maria Stefania Infante, Maria Jose Sanchez, Antonia Sampol, Javier de la Rubia

Summary: This study suggests that tandem ASCT can improve the poor prognosis of patients with HR cytogenetic to some extent, which holds clinical significance for newly diagnosed patients with MM and HR cytogenetic.

LEUKEMIA & LYMPHOMA (2022)

Article Hematology

Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma

Carmen Martinez, Manuel Espeso de Haro, Samuel Romero, Antonio Gutierrez, Eva Domingo-Domenech, Ana P. Gonzalez-Rodriguez, Izaskun Zeberio, Maria Paz Martinez-Badas, Antonia Rodriguez-Izquierdo, Cecilia Carpio, Mariana Bastos-Oreiro, Jose Angel Hernandez-Rivas, Rolando Vallansot, Nicholas Kelleher, Francisco J. Diaz-Galvez, Tamara Torrado, Arturo Pereira, Ramon Garcia-Sanz

Summary: The AETHERA trial demonstrated that BV consolidation after ASCT can improve PFS in high-risk HL patients. BV is frequently used as front-line treatment and/or pre-ASCT salvage therapy. Real-life data analysis shows that BV consolidation can improve PFS regardless of BV exposure prior to ASCT.

ANNALS OF HEMATOLOGY (2023)

Meeting Abstract Hematology

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)

Maria-Victoria Mateos, Joaquin Martinez-Lopez, Paula Rodriguez-Otero, Jesus San-Miguel, Veronica Gonzalez-Calle, Marta Sonia Gonzalez, Albert Oriol, Norma C. Gutierrez, Rafael Rios, Laura Rosinol Dachs, Miguel Angel Alvarez, Joan Bargay, Ana Pilar Gonzalez, Fernando Escalante, Adrian Alegre, Belen Inigo, Javier de la Rubia, Ana Isabel Teruel, Felipe De Arriba, Luis Palomera, Miguel-Teodoro Hernandez, Javier Lopez Jimenez, Marta Reinoso Segura, Aranzazu Garcia Mateo, Enrique M. Ocio, Joan Blade, Juan-Jose Lahuerta, Maria Teresa Cedena, Noemi Puig, Bruno Paiva

Editorial Material Oncology

The Emerging Role of NK Cells in Immune Checkpoint Blockade

Alejandra Martinez-Perez, Candelaria Aguilar-Garcia, Segundo Gonzalez

CANCERS (2022)

Article Oncology

BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia

Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Alejandra Martinez-Perez, Ana P. Gonzalez-Rodriguez, Angel R. Payer, Esther Gonzalez-Garcia, Candelaria Aguilar-Garcia, Sara Gonzalez-Rodriguez, Alejandro Lopez-Soto, Alejandra Garcia-Torre, Segundo Gonzalez

Summary: Patients with CLL show increased expression of inhibitory immune checkpoint BTLA on CD4+ and CD8+ T lymphocytes, leading to suppression of antitumor responses. Blocking BTLA enhances CD8+ T cell-mediated anti-leukemic responses, suggesting its potential as a therapeutic target in CLL.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)

Review Oncology

Chemo-Immunotherapy: A New Trend in Cancer Treatment

Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Ana P. Gonzalez-Rodriguez, Alejandra Martinez-Perez, Juan P. Rodrigo, Juana M. Garcia-Pedrero, Segundo Gonzalez

Summary: Chemotherapy combined with immunotherapy, known as chemoimmunotherapy, is an emerging treatment option for cancer that aims to increase the efficacy of cancer treatment by targeting cancer cells and boosting the immune system's ability to fight cancer. Promising results have been observed in studies treating various types of cancer with chemoimmunotherapy, but further investigation is needed to determine the optimal dosing, timing, and sequencing of these treatments.

CANCERS (2023)

Article Cell Biology

The secretome atlas of two mouse models of progeria

Diego Quintana-Torres, Alejandra Valle-Cao, Pablo Bousquets-Munoz, Sandra Freitas-Rodriguez, Francisco Rodriguez, Alejandro Lucia, Carlos Lopez-Otin, Alejandro Lopez-Soto, Alicia R. Folgueras

Summary: This study conducted a global plasma proteomic analysis in progeroid mouse models and found several upregulated proteins related to cardiovascular disease, the main cause of death in HGPS patients. The plasma proteome of progeroid mice exhibited an old signature, indicating accelerated aging. Furthermore, specific differences were observed in the circulating proteins between physiological and premature aging, highlighting potential biomarkers and therapeutic targets.

AGING CELL (2023)

Meeting Abstract Oncology

Randomized phase 2 study of weekly carfilzomib 70 mg/m2 and dexamethasone plus/minus cyclophosphamide in relapsed and/or refractory multiple (MM) patients (GEM-KyCyDex)

Borja Puertas, Veronica Gonzalez, Anna Sureda, Ma Jose Moreno, Albert Oriol, Ma Esther Gonzalez, Laura Rosinol, Jordi Lopez, Fernando Escalante, Joaquin Martinez Lopez, Estrella Carrillo, Esther Clavero, Ana Pilar Gonzalez Rodriguez, Victoria Dourdil, Felipe de Arriba de la Fuente, Marta Sonia Gonzalez, Jaime Perez de Oteyza, Miguel Teodoro Hernandez, Aranzazu Garcia Mateo, Joan Blade, Juan Jose Lahuerta Palacios, Jesus San-Miguel, Enrique Ocio, Maria-Victoria Mateos

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

Meeting Abstract Oncology

Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics: a retrospective study of the PETHEMA/Spanish Myeloma Group (GEM)

Ana Villalba, Pilar Lloret, Ana Pilar Gonzalez Rodriguez, Javier Arzuaga-Mendez, Noemi Puig, Mario Arnao, Jose Maria Arguinano, Maria Jimenez, Marta Canet, Ana I. Teruel, Maria Sola, Francisco J. Diaz, Cristina Encinas, Antonio Garcia, Laura Rosinol, Alexia Suarez, Marta Sonia Gonzalez, Isabel Izquierdo, Miguel Teodoro Hernandez, Maria Stefania Infante, Maria Jose Sanchez, Antonia Sampol, Javier De la Rubia

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

Meeting Abstract Biophysics

Bloodstream infections in hematopoietic stem cell transplant recipients colonized by multidrug-resistant bacteria

A. P. Gonzalez-Rodriguez, P. Palomo-Moraleda, J. Suarez-Paneda, J. Zanabili, S. Gonzalez-Muniz, L. R. Morais Bras, S. Lorenzo Herrero, C. Sordo-Bahamonde, A. Martinez-Perez, A. J. Gonzalez-Huerta

BONE MARROW TRANSPLANTATION (2022)

暂无数据